![Grifois, S.A.](/_next/image?url=https%3A%2F%2Fcdn.itspluto.com%2Fstock%2Fgrfs.png&w=48&q=75)
Grifois, S.A.
Compare this stock
GRFS Stock Report Card
$
66%
Performance
Score:
100/100
GRFS returned 24.01% in the last 12 months. Based on SPY's performance of -13.75%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
Score:
75/100
4 analysts offer 12-month price targets for GRFS. Together, they have an average target of 0, the most optimistic target put GRFS at 0 within 12-months and the most pessimistic has GRFS at 0.
Technicals
Score:
89/100
GRFS receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.
Earnings
Score:
10/100
GRFS has missed earnings 7 times in the last 20 quarters.
Profit
Score:
71/100
Out of the last 20 quarters, GRFS has had 19 profitable quarters and has increased their profits year over year on 7 of them.
Volatility
Score:
57/100
GRFS has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.
Grifois, S.A. Summary
Nasdaq / GRFS
Healthcare
Drug Manufacturers - General
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
GRFS scored highly on our reportcard. Here are some similar companies and how they performed.